《平价医疗法案》:保险对糖尿病生物标志物的影响
本研究为回顾性观察性队列研究,利用178家社区健康中心电子健康记录,评估10个医疗补助扩展州成年糖尿病患者在ACA扩展前后24个月糖尿病相关生物标志物变化,比较新获保险与持续有保险、间断有保险及持续无保险患者。结果显示新获保险患者HbA1c、收缩压、舒张压及LDL胆固醇改善均优于持续无保险患者,研究提示通过ACA获得保险可促进适当糖尿病照护。
要点
- 新获保险患者调整后平均HbA1c从8.24%降至8.17%,持续无保险患者从8.12%升至8.29%(DID -0.24%;P < 0.001)。
- 新获保险患者较持续无保险患者收缩压DID -1.8 mmHg(P < 0.001)、舒张压DID -1.0 mmHg(P < 0.001)、LDL DID -3.3 mg/dL(P < 0.001)。
- 扩展前3个月内HbA1c升高的患者中,新获保险者较持续无保险者24个月后HbA1c达标的可能性更高(HR 1.25;95% CI 1.02-1.54)。
核心结论
- ACA实施后,新获保险患者的糖尿病相关生物标志物改善程度大于持续无保险、间断有保险或持续有保险患者。
- 研究结果提示通过ACA获得保险可促进适当糖尿病照护的获取,从而改善糖尿病相关生物标志物。
研究设计与样本
- 回顾性观察性队列研究,使用ADVANCE网络中178家社区健康中心的电子健康记录数据。
- 纳入10个医疗补助扩展州的成年糖尿病患者(n = 25,279),比较新获保险与持续有保险、间断有保险及持续无保险患者ACA扩展前后的变化。
- 主要结局为ACA扩展前24个月至扩展后24个月糖化血红蛋白、收缩压、舒张压及LDL胆固醇水平的变化。
主要发现
- 新获保险患者调整后平均HbA1c从8.24%(67 mmol/mol)降至8.17%(66 mmol/mol),持续无保险患者从8.12%(65 mmol/mol)升至8.29%(67 mmol/mol),DID -0.24%(P < 0.001)。
- 新获保险患者较持续无保险患者调整后平均收缩压DID -1.8 mmHg(P < 0.001)、舒张压DID -1.0 mmHg(P < 0.001)、LDL DID -3.3 mg/dL(P < 0.001)。
- 扩展前3个月内HbA1c升高的患者中,新获保险患者较持续无保险患者24个月后HbA1c达标的可能性更高(HR 1.25;95% CI 1.02-1.54)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to understand how Affordable Care Act (ACA) Medicaid expansion insurance coverage gains are associated with changes in diabetes-related biomarkers. RESEARCH DESIGN AND METHODS: This was a retrospective observational cohort study using electronic health record data from 178 community health centers (CHCs) in the ADVANCE (Accelerating Data Value Across a National Community Health Center Network) network. We assessed changes in diabetes-related biomarkers among adult patients with diabetes in 10 Medicaid expansion states (n = 25,279), comparing newly insured with continuously insured, discontinuously insured, and continuously uninsured patients pre- to post-ACA expansion. Primary outcomes included changes from 24 months pre- to 24 months post-ACA in glycosylated hemoglobin (HbA1c), systolic (SBP) and diastolic (DBP) blood pressure, and LDL cholesterol levels. RESULTS: Newly insured patients exhibited a reduction in adjusted mean HbA1c levels (8.24% [67 mmol/mol] to 8.17% [66 mmol/mol]), which was significantly different from continuously uninsured patients, whose HbA1c levels increased (8.12% [65 mmol/mol] to 8.29% [67 mmol/mol]; difference-in-differences [DID] -0.24%; P < 0.001). Newly insured patients showed greater reductions than continuously uninsured patients in adjusted mean SBP (DID -1.8 mmHg; P < 0.001), DBP (DID -1.0 mmHg; P < 0.001), and LDL (DID -3.3 mg/dL; P < 0.001). Among patients with elevated HbA1c in the 3 months prior to expansion, newly insured patients were more likely than continuously uninsured patients to have a controlled HbA1c measurement by 24 months post-ACA (hazard ratio 1.25; 95% CI 1.02-1.54]. CONCLUSIONS: Post-ACA, newly insured patients had greater improvements in diabetes-related biomarkers than continuously uninsured, discontinuously insured, or continuously insured patients. Findings suggest that health insurance gain via ACA facilitates access to appropriate diabetes care, leading to improvements in diabetes-related biomarkers.
引用
- Marino M, Angier H, Springer R, et al. The Affordable Care Act: Effects of Insurance on Diabetes Biomarkers. Diabetes Care. 2020. PMID: 32611609. doi:10.2337/dc19-1571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。